Now Patient

nowpatient.com

Now Patient is a new health app for NHS patients, created by leading telehealth organisation Now Healthcare Group. Available for iOS and Android devices, Now Patient provides FREE repeat medicines delivered to your home and FREE access to GPs and nurses via smartphone-based video consultation.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NEW JERSEY PHARMACEUTICAL COMPANY DONATES 400,000 TABLETS TO LOUISIANA FOR CLINICAL TRIALS IN COVID-19 TREATMENT

WBRZ- | March 30, 2020

news image

Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...

Read More

Pharma Tech

PHIO PHARMACEUTICALS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2020 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

Phio Pharmaceuticals Corp | October 26, 2020

news image

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually...

Read More

Business Insights

ASAHI KASEI BIOPROCESS TO SHOWCASE AWARD-WINNING MOTIV™ BUFFER MANAGEMENT TECHNOLOGY FOR PHARMACEUTICAL MANUFACTURING AT ACHEMA 2022

Asahi Kasei Bioprocess | August 01, 2022

news image

Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt this August. Winner of “Best in Show” at Interphex in 2017, “Technology of the Decade” from Bioprocess international in 2012 and originator of the concept for inline buffer formulation (IBF™), Asahi Kasei Bioprocess is a market leader that keeps pharmaceutical production mo...

Read More

Pharmacy Market

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa | May 19, 2021

news image

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More
news image

NEW JERSEY PHARMACEUTICAL COMPANY DONATES 400,000 TABLETS TO LOUISIANA FOR CLINICAL TRIALS IN COVID-19 TREATMENT

WBRZ- | March 30, 2020

Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...

Read More
news image

Pharma Tech

PHIO PHARMACEUTICALS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2020 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

Phio Pharmaceuticals Corp | October 26, 2020

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually...

Read More
news image

Business Insights

ASAHI KASEI BIOPROCESS TO SHOWCASE AWARD-WINNING MOTIV™ BUFFER MANAGEMENT TECHNOLOGY FOR PHARMACEUTICAL MANUFACTURING AT ACHEMA 2022

Asahi Kasei Bioprocess | August 01, 2022

Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt this August. Winner of “Best in Show” at Interphex in 2017, “Technology of the Decade” from Bioprocess international in 2012 and originator of the concept for inline buffer formulation (IBF™), Asahi Kasei Bioprocess is a market leader that keeps pharmaceutical production mo...

Read More
news image

Pharmacy Market

NARRATIVA RAISES $1.3M TO HELP PHARMA COMPANIES ACCELERATE THE FDA DRUG APPROVAL PROCESS

Narrativa | May 19, 2021

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). Th...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us